ADVA
8.9.2020 09:02:18 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the Luxembourg Commercial Internet Exchange (LU-CIX) is increasing the security and availability of its services with the ADVA ALM fiber monitoring solution. The technology provides real-time network visibility, enabling LU-CIX to quickly locate and resolve all fiber issues. Deployed in the internet exchange company’s backbone infrastructure, the ADVA ALM delivers comprehensive in-service assurance. It’s now empowering LU-CIX to accurately pinpoint areas of degradation, instantly initiate countermeasures and redirect traffic away from degraded optical paths. The compact and low-power solution helps avoid outages and enables LU-CIX to track its SLAs. ADVA’s partner Telindus, a brand of Proximus Luxembourg, also played a key role in the deployment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005221/en/
“We needed a solution that delivers precise, automated, up-to-the-minute root-cause analysis combined with permanent measurement. That’s why we chose the ADVA ALM. It enables our team to tackle issues more quickly and efficiently, while also addressing an area of security exposure,” said Michel Lanners, CIO, LU-CIX. “One of the key advantages of the ADVA ALM is that it offers significant improvement without a major addition to our existing network. It delivers total insight and full control without significant investment. What’s more, the technology enables us to improve the integrity of our network and detect eavesdropping attacks. With the ADVA ALM, we can remotely measure attenuation and stay one step ahead of attacks using a splitter or bending coupler.”
The ADVA ALM is now delivering precise, real-time insight into the integrity and performance of LU-CIX’s optical transport infrastructure. With its ease of use and intuitive GUI, the in-service monitoring equipment provides complete network assurance, enabling the root cause of link outages to be immediately pinpointed. Issues can now be identified in seconds and the right measures engaged, saving the company both time and money. The ADVA ALM also makes it straightforward to separate faults with active devices from problems in the fiber plant. Another key advantage is its transparent, service-agnostic monitoring, which is completely independent of transported data. That means the ADVA ALM delivers complete assurance with no application interference.
“Our ALM now ensures that LU-CIX has an intricate understanding of its fiber network. For maintenance teams, that means no more false alarms, no unnecessary site visits and no wasted hours finding faults. Now problems can be diagnosed and dealt with long before they affect services. Not only will this help to reduce operational expenses and maximize resource efficiency, but it’s also a key tool for maintaining valuable SLAs,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “LU-CIX is crucial to Luxembourg’s internet sector and one of Europe’s key internet hubs. By harnessing our unique plug-and-play device to further enhance the stability and efficiency of its infrastructure, it can continue to provide a secure and trusted environment in the heart of Europe.”
“This deployment is already bringing major benefits to LU-CIX and its customers. It’s enabling the internet exchange to avoid performance issues by rapidly responding to defects and degradation in its fiber network. Now LU-CIX can proactively reroute traffic and operating teams can take targeted action to fix faults,” said William Malingrey, pre-sales consultant, network solutions, Telindus. “We’re committed to providing the most innovative technologies available to support our customers’ business strategies and digital transformation. The ADVA ALM is a uniquely affordable and space-efficient solution that makes a real difference. It’s now giving LU-CIX total visibility and control of its fiber assets and supporting simpler, more cost-efficient and more sustainable practices.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About LU-CIX
LU-CIX, the LUxembourg Commercial Internet eXchange was founded in 2009 based on a not-for-profit membership association with an open and neutral philosophy. Its aim is to develop the Internet and support the data center community in Luxembourg. As well as providing the technical infrastructure LU-CIX also makes a major contribution to the Luxembourg Internet community through its leading industry event, Luxembourg Internet Days, which takes place in November every year and attracts over a thousand industry experts and decision makers from around the globe. LU-CIX also runs the datacenters-in-europe.com website, which provides a shared communication platform for all the players in the Luxembourg data center and Internet arena and promotes Luxembourg as the best place for your European data center and ICT business in the heart of Europe. More information at www.lu-cix.lu .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005221/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
